Fitusiran is under clinical development by Sanofi and currently in Phase III for Hemophilia B (Factor IX Deficiency). According to GlobalData, Phase III drugs for Hemophilia B (Factor IX Deficiency) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Fitusiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fitusiran (SAR-439774) is under development for the treatment of hemophilia A and B and other rare bleeding disorders. ALN-AT3 is administered through subcutaneous route. It is developed based on GalNAc-siRNA conjugate delivery platform and enhanced stabilization chemistry (ESC)-GalNAc delivery platform.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of Fitusiran’s drug-specific PTSR and LoA scores, buy the report here.